Company research
GT Biopharma, Inc.
CIK 109657Updated Sep 26, 2026
SecurityGTBP · NASDAQ · equity
Name history
GT Biopharma, Inc. · through Sep 21, 2026OXIS INTERNATIONAL INC · through Jul 25, 2017
GTBP price & chart
Loading TradingView…
NASDAQ:GTBP on TradingView ↗About the company
We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE®”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”). Once bound to an NK cell, our moieties are designed to activate the NK cell to direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted cell’s death. TriKE®s can be designed to target any number of tumor antigens, including B7-H3, HER2, CD33 and PDL1, on hematologic malignancies or solid tumors and do not require patient-specific customization. We believe our TriKE® and Dual Targeting TriKE® platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome and fewer neurological complications. Our preclinical data su…
In the news
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs ↗
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet ↗
Recent filings
8-K filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 3.02, 3.03, 5.03, 9.01
SCHEDULE 13G filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 3.02, 3.03, 5.03, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 3.03, 5.03, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,106,000Source | 4,232,000Source | 14,109,000Source | 16,736,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,811,000Source | 3,951,000Source | 1,079,000Source | 5,672,000Source |
| Assets, CurrentUSD | 8,106,000Source | 4,232,000Source | 14,056,000Source | 16,562,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 567,000Source | 188,000Source | 84,000Source | 54,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 53,000Source | 165,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | — | — | 6,633,000Source | 5,002,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 1,000Source | 1,000Source | 1,000Source |
| Common Stock, Value, IssuedUSD | 26,000Source | 2,000Source | 1,000Source | 33,000Source |
| Additional Paid in CapitalUSD | 729,661,000Source | 693,554,000Source | 689,539,000Source | 686,168,000Source |
| Retained Earnings (Accumulated Deficit)USD | -723,901,000Source | -695,227,000Source | -682,065,000Source | -674,468,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,787,000Source | -1,670,000Source | 7,476,000Source | 11,734,000Source |
| Liabilities and EquityUSD | 8,106,000Source | 4,232,000Source | 14,109,000Source | 16,736,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,319,000Source | 5,902,000Source | 6,633,000Source | 4,938,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 58,000Source | 110,000Source |
| Accounts Payable, CurrentUSD | 748,000Source | 3,853,000Source | 4,328,000Source | 3,140,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 64,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,560,000Source | 1,797,000Source | 1,195,000Source | 1,669,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 14,000,000Source | — |
| Short-term InvestmentsUSD | — | — | 12,893,000Source | 10,836,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 432,000Source | — | — | 7,700,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -12,914,000Source | -12,904,000Source | -8,852,000Source | -15,217,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 12,893,000Source | -2,009,000Source | 12,145,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 15,775,000Source | 2,976,000Source | 6,268,000Source | -224,000Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,861,000Source | 2,965,000Source | -4,593,000Source | -3,296,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,905,000Source | 4,044,000Source | 1,079,000Source | 5,672,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 213,000Source | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 14,000,000Source | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | 119,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 200,000Source | — | — | 31,000Source |
| InterestExpenseNonoperatingUSD | 127,000Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 48,000Source | -30,000Source |
| Net Income (Loss) Attributable to ParentUSD | -28,354,000Source | -13,162,000Source | -7,597,000Source | -20,884,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -34,449,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -15,932,000Source | 1,202,000Source | 5,979,000Source | 373,000Source |
| Operating ExpensesUSD | — | — | 13,576,000Source | 21,257,000Source |
| Other Nonoperating Income (Expense)USD | 156,000Source | — | 20,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | 6,268,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 8,950,000Source | 8,566,000Source | 7,110,000Source | 12,446,000Source |
| Operating Income (Loss)USD | -12,422,000Source | -14,364,000Source | -13,576,000Source | -21,257,000Source |
| Other Nonoperating Income (Expense)USD | 156,000Source | — | 20,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -28,354,000Source | -13,162,000Source | -7,597,000Source | -20,884,000Source |
| Earnings Per Share, BasicUSD per share | -6.68Source | -6.94Source | -5.64Source | -0.66Source |
| Earnings Per Share, DilutedUSD per share | -6.68Source | -6.94Source | -5.64Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 5,513,255Source | 1,897,375Source | 1,347,713Source | 31,868,024Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 5,513,255Source | 1,897,375Source | 1,347,713Source | — |
| Interest Expense (non-operating)USD | 127,000Source | — | — | — |
| Additional Financial Items | ||||
| Interest ExpenseUSD | — | — | 213,000Source | 8,000Source |
| Interest Income, OtherUSD | 123,000Source | 402,000Source | 780,000Source | 292,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -34,449,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -15,932,000Source | 1,202,000Source | 5,979,000Source | 373,000Source |
| Operating ExpensesUSD | — | — | 13,576,000Source | 21,257,000Source |
| Research and Development ExpenseUSD | 3,472,000Source | 5,798,000Source | 6,466,000Source | 8,811,000Source |
Offerings
Registration 333-295461
Registration 333-292856
Registration 333-291060
Registration 333-287963
Registration 333-284032
Filing attachments
ex4-1.htm · 8-K · 2026-09-15
EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-2.htm · 8-K · 2026-09-15
EX-4.2 4 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January 2026 SAN FRANCISCO, CALIFORNIA, November 14, 2025 /Globe newswire/ -…
Read attachment ↗ex4-1.htm · 8-K · 2025-05-13
EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-2.htm · 8-K · 2025-05-13
EX-4.2 4 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-1.htm · 8-K · 2025-04-04
EX-4.1 2 ex4-1.htm Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTIO…
Read attachment ↗